Top

Published in:

01-06-2020 | Esophageal Cancer | Editorial

Paradox of age-specific incidence rates of second primary cancer in individuals with esophageal cancer

Author: Tomonori Yano

Published in: Journal of Gastroenterology | Issue 6/2020

Excerpt

Aging must be the leading cause of cancer in clinical. In recent, translational research using samples of esophageal epithelium suggests that carcinogenesis of esophageal squamous cell carcinoma (ESCC) is related to age-related expansion of NOTCH1 mutated clones associated with exposure to large amounts of tobacco and alcohol consumption [1]. …

Yokoyama A, Kakiuchi N, Yoshizato T, et al. Age-related remodeling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565:312–7.CrossRef

Maekawa A, Ishihara R, Iwatsubo T, et al. High incidence of head and neck cancers after endoscopic resection for esophageal cancer in younger patients. J Gastroenterol. 2019. https://doi.org/10.1007/s00535-019-01653-y.CrossRefPubMed

Matsubara T, Yamada K, Nakagawa A, et al. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;1(21):4336–411.CrossRef

Muto M, Nakane M, Katada C, et al. Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer. 2004;15(101):1375–81.CrossRef

Muto M, Minashi K, Yano T, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol. 2010;20(28):1566–72.CrossRef

Morimoto H, Yano T, Yoda Y, et al. Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma. World J Gastroenterol. 2017;14(23):1051–8.CrossRef

Katada C, Yokoyama T, Yano T, et al. Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 2016;151:860–9 (e7).CrossRef

Abiko S, Shimizu Y, Miyamoto S, et al. Risk assessment of metachronous squamous cell carcinoma after endoscopic resection for esophageal carcinoma based on the genetic polymorphisms of alcoholdehydrogense-1B aldehyde dehydrogenase-2: temperance reduces the risk. J Gastroenterol. 2018;53:1120–30.CrossRef

Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;13(345):784–9.CrossRef

10.

Fenoglio-Preiser C, Carneiro F, Correa R, et al. Gastric carcinoma world health organization classification of tumors pathology and genetics of tumors of the digestive system. 2000; p. 39–52

11.

Hayakawa Y, Sethi N, Sepulveda AR, et al. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev. 2016;16:305–18.CrossRef

12.

Cancer Genome Atlas Research Network, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef

Title: Paradox of age-specific incidence rates of second primary cancer in individuals with esophageal cancer
Author: Tomonori Yano
Publication date: 01-06-2020
Publisher: Springer Singapore
Keywords: Esophageal Cancer
Gastric Cancer
Esophageal Cancer
Gastric Cancer
Published in: Journal of Gastroenterology / Issue 6/2020
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-020-01687-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn’s disease

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study

Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

Correction to: Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradication therapy

Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

Objective evaluation for treat to target in Crohn’s disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials